Butyrate-Producing Microbe Composition with a Mucin-Degrading Intermediary
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current microbiome therapies face challenges in effectively engrafting butyrate-producing microbes in subjects, particularly in the absence of mucin-degrading microbes, which are essential for creating a conducive environment for their growth and colonization.
Innovation Solution
A composition comprising a therapeutically-effective amount of isolated and purified butyrate-producing microbes, specifically designed to enhance engraftment in the presence of mucin-degrading microbes, which degrade mucin to produce energy sources and short-chain fatty acids that promote butyrate production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If butyrate-producing microbes are administered alone, then the composition is simple and easy to manufacture, but engraftment fails in subjects lacking mucin-degrading microbes
Solution Approach 1:
The mucin-degrading microbe acts as an intermediary that modifies the gut environment by degrading mucin to produce energy sources and short-chain fatty acids, which then enable the engraftment of butyrate-producing microbes. This mediator approach resolves the contradiction by creating the necessary conditions for successful engraftment without directly complicating the butyrate-producing microbe formulation itself.
Solution Approach 2:
The mucin-degrading microbe performs preliminary action by degrading mucin and creating a conducive environment (energy sources and short-chain fatty acids) before the butyrate-producing microbes can successfully engraft. This preliminary environmental preparation ensures reliable engraftment while maintaining composition simplicity.
2Reliability
If mucin-degrading microbe is added to enhance butyrate-producing microbe engraftment, then engraftment success increases, but composition complexity increases
Solution Approach 1:
The mucin-degrading microbe serves as a biological intermediary that naturally creates the necessary environment for butyrate-producing microbe engraftment through mucin degradation. This approach maintains ease of manufacture because both microbes can be formulated together in a single composition without requiring complex separate formulation processes.
3Quantity of substance
If butyrate-producing microbe is administered without mucin-degrading microbe, then composition is simpler, but engraftment abundance increases by less than one order of magnitude
Solution Approach 1:
The mucin-degrading microbe performs preliminary environmental preparation by degrading mucin to produce energy sources and short-chain fatty acids, which creates optimal conditions for butyrate-producing microbe proliferation. This preliminary action enables the quantity of butyrate-producing microbes to increase by at least one order of magnitude, resolving the contradiction between simplicity and effectiveness.
Solution Approach 2:
The mucin-degrading microbe changes key environmental parameters (availability of energy sources and short-chain fatty acids) by degrading mucin. These parameter changes create favorable conditions that enable significant increases in butyrate-producing microbe abundance while maintaining composition simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves significant engraftment of butyrate-producing microbes, indicated by at least a one-order of magnitude increase in their nucleic acid abundance, thereby enhancing gut health and potentially treating microbiome-related disorders.
Implementation Method 1
mucin-degrading microbes, which degrade mucin to produce energy sources and short-chain fatty acids that promote butyrate production
Implementation Method 2
butyrate-producing microbes... increases in a presence of a mucin-degrading microbe... enhance engraftment
Data Source
AI summary
The disclosure provides compositions and methods for therapeutic administration of the compositions to treat comorbidities associated with gut dysbiosis. The disclosure also provides compositions and methods for increasing engraftment of administered microbes. The disclosure also provides methods for stool sample collection.